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Abstract
Objective: This study was performed to evaluate the effect of prolonged treatment with the dopamine
agonist quinagolide on serum gonadotropin and a-subunit concentrations and tumor volume in
patients with clinically non-functioning pituitary adenomas (CNPA).
Design: Ten patients with CNPA were treated with quinagolide (0.3 mg daily). The median duration of
treatment was 57 months (range 36±93 months). Blood samples for measurement of serum
gonadotropin and a-subunit concentrations were drawn before treatment, after 5 days, and at
each outpatient visit. Computerized tomography or magnetic resonance imaging of the pituitary
region and Goldmann perimetry were done before and at regular intervals during treatment.
Results: A significant decrease of serum FSH, LH or a-subunit concentrations was found in nine
patients. The levels remained low during the entire treatment period. In two out of three patients with
pre-existing visual field defects a slight improvement was shown during the first months of treatment,
but eventually deterioration occurred in all three patients. A fourth patient developed unilateral
ophthalmoplegia during treatment. During the first year tumor volume decreased in three patients,
but in two of them regrowth occurred after a few months. In six patients progressive tumor growth
occurred despite sustained suppression of gonadotropin or a-subunit levels.
Conclusions: Long-term treatment of patients with CNPA with high doses of the dopamine agonist
quinagolide could not prevent progressive increase in tumor size in most patients. It remains
unproven whether quinagolide retards CNPA growth. Additional studies are needed to investigate
whether subgroups of patients, e.g. those with positive dopamine receptor scintigraphy or those with
marked hypersecretion of intact gonadotropins or subunits, will respond more favorably to treatment
with dopamine agonists.
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Introduction
Approximately 25±30% of pituitary adenomas are
classified as clinically non-functioning (1±5). Because
patients harboring these tumors lack clinical signs of
hormone excess, the diagnosis is usually made at an
advanced stage. Surgical removal is therefore often
incomplete and at present there is no established
medical treatment available. The majority of these
tumors are in fact poorly secreting, rather than
completely non-secreting. In cell culture they usually
release gonadotropins or their subunits (6±8). Phar-
macological suppression of this hormone production
could theoretically induce tumor shrinkage, analogous
to the effects of dopamine agonists in patients with
prolactinomas and somatostatin analogues in patients
with growth hormone (GH)-producing adenomas (9,
10).
In general, clinically non-functioning pituitary ade-
nomas (CNPA) express dopamine D2 receptors on their
cell membranes (11, 12). This is confirmed by new in
vivo dopamine receptor scintigraphy techniques with
the iodinated benzamides 123I-IBZM or 123I-epidepride
(13±16). The dopamine agonist bromocriptine can
suppress the synthesis and secretion of gonadotropins
and a -subunits by CNPA cells in vitro (17±19). It also
reduces a-subunit mRNA accumulation in tumor
tissue removed from patients with pure a-subunit
secreting tumors (18). Therefore several investigators
have tried dopamine agonist therapy, usually bromo-
criptine, in patients with CNPA. The results are rather
disappointing, however, showing improvement of
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visual field defects and/or reduction of tumor mass in
only a small number of patients (11, 20±24). Since
bromocriptine is generally not well tolerated in high
doses, rather low doses were used in these studies. In
addition, the treatment periods were generally short.
The density of dopamine receptors on CNPA cells is
much lower than on prolactinoma cells. Moreover,
prolonged incubation with bromocriptine in high
concentrations is needed to obtain a significant
reduction of gonadotropin and a-subunit release in
vitro (19). This suggests that sustained treatment with
high doses of a dopamine agonist is needed to obtain
tumor shrinkage.
The new generation of more powerful and more
selective dopamine agonists might provide a useful
alternative for bromocriptine (25). These drugs are
better tolerated than bromocriptine, allowing the use of
higher doses. Our group has published preliminary
results with the long-acting non-ergot dopamine agonist
quinagolide in five patients with CNPA (26). At a final
daily dose of 0.3 mg during 12±18 months a significant
decrease in serum follicle-stimulating hormone (FSH)
and/or a-subunit concentrations was induced in four
patients, tumor shrinkage in one, and improvement in
visual field defects in two. The drug was well tolerated.
In order to evaluate the long-term effect of quinago-
lide in vivo we followed serum gonadotropin and a-
subunit concentrations and tumor volume in ten
patients with CNPA, who were treated with the
dopamine agonist for at least 3 years. Tumor volume
was carefully measured using a surface to volume
summation method and a mathematical method based
on the three axes of the tumor.
Subjects and methods
We studied ten patients with CNPA. Short-term (12±18
months) follow-up data of four patients (patients 2, 3, 7, 8)
were published previously by Kwekkeboom & Lamberts
(26). CNPA was defined as the presence of a solid pituitary
tumor without clinical signs of hormonal hypersecretion
and lacking clinical and radiological characteristics of
non-pituitary tumors (such as craniopharyngiomas,
meningiomas, metastases of distant malignant tumors or
aneurysms of the internal carotid artery). Patients with
pituitary apoplexia or radiological evidence of bleeding,
necrosis or cystic structures in the tumor were excluded.
None of the patients had received prior medical, surgical or
radiation therapy for the pituitary adenoma.
All patients gave informed consent to participate in
the study, which was approved by the hospital ethics
committee. Medical treatment with quinagolide was
started at a daily dose of 0.075 mg. The dose was
progressively increased to the final daily dose of 0.3 mg
within 1 month. Reasons for choosing quinagolide
treatment were either the presence of relative contra-
indications to surgery or refusal of surgery by the
patient. Patients were regularly followed at the out-
patient clinic for at least 3 years.
Pretreatment serum gonadotropin and a-subunit
concentrations were determined from samples drawn
on a control day hourly for 12 h. In six patients
additional hourly sampling for 12 h was performed 5
days after starting quinagolide treatment. Thereafter
blood samples were drawn at each visit to the
outpatient department. Prolactin (PRL) levels were
measured to assess compliance to the treatment.
PRL, insulin-like growth factor-I (IGF-I), GH, thyroid-
stimulating hormone (TSH) and adrenocorticotropic
hormone (ACTH) were measured using kits obtained,
respectively, from IRE-Medgenix, Brussels, Belgium
(PRL, IGF-I); Sorin, Milan, Italy; Behring, Marburg,
Germany; and Amersham International, Amersham,
Bucks, UK. FSH and luteinizing hormone (LH) were
measured using IRMA kits supplied by IRE-Medgenix,
Brussels, Belgium. The sensitivity of these assays was
0.5 U/l. a-Subunit was measured by RIA, using
antibodies purchased from UCB, Brussels, Belgium.
The sensitivity of the a-subunit assay was 0.3 mg/l. The
intra- and inter-assay coefficients of variation were
respectively ,5 and ,15% for LH, ,3 and ,8% for
FSH, and ,6 and ,11% for a-subunit (27).
Computerized tomographic (CT) scans or magnetic
resonance imaging (MRI) of the pituitary region and
Goldmann perimetry were done before and at
regular intervals during treatment. CT scans and/or
MRI images were used to estimate tumor volume.
The scans were digitized using a Hewlett Packard
ScanJet II cx/t flatbed scanner (Hewlett Packard
Company, Palo Alto, CA, USA). The scanner was
operated by a Macintosh LC 475 20/250 mb
computer (Apple Computer Inc., Cupertino, CA,
USA), utilizing Desk scan II software (Hewlett
Packard). Files were read by the NIH Image 1.27
digital image analysis program (Shareware; National
Institutes of Health, Baltimore, MD, USA). The scale
was calibrated from pixels to millimeters using the
scale bar printed on scans. All measurements were
performed by the same observer. Two methods of
volume calculation were used: a surface to volume
summation method and a method based on the three
axes of the tumor (28). In the surface to volume
summation method the tumor area was outlined
using the computer mouse. The surface of the tumor
section was calculated and multiplied with the slice
thickness. The total volume of the tumor was
calculated by adding up these values. Duong et al.
(29) published an error analysis of this method,
showing acceptable measurement deviations from
known volumes. In the other method the x, y and
z radii were measured in the frontal, sagittal and
coronal planes respectively. Assuming a spherical
volume, the formula 4=3pr3 was used for volume
calculation, r being the mean of the x, y and z radii.
All measurements of tumor volume were performed
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by the same technician, who was blinded to clinical
responses. Measurements were done twice and mean
results used.
Individual hormone levels were evaluated using
ANOVA. For the comparison of the means the Newman±
Keuls method was applied. P values ,0.05 were
considered significant.
Results
Patient data and hormone levels are listed in Table 1.
No apparent hypersecretion of gonadotropins or a-
subunits was shown, except in one patient (patient 7)
who had a slightly elevated serum a-subunit level.
Serum levels of PRL were slightly elevated in four
Figure 1. Comparison between two methods of estimation of tumor
volume (cm3).
Table 1 Patient data and LH, FSH and a-subunit levels before and during treatment with quinagolide.
Age Total duration of Quinagolide treatment LH FSH a -subunit
Patient Sex (years) follow-up (months) (months) (U/I; mean (range)) (U/I; mean (range)) (mg/l; mean (range))
1 M 67 56 Before 1.4 (0.9±1.8) 1.4 (0.6±2.2) 0.4 (0.3±0.6)
1±3 1.0 0.9 Ð
3±12 0.7 (0.4±1.0)* 1.4 (1.0±1.9) 0.6 (0.5±0.6)
.12 0.5 (0.4±0.8) 1.2 (0.4±2.4) 0.5 (0.2±0.8)
2 M 62 91 Before 0.6 (0.5±0.6) 8.0 (6.8±9.4) 0.5 (0.5±0.6)
1±3 0.5 (0.4±0.6) 1.5 (0.5±2.2)** 0.4 (0.2±0.5)*
3±12 0.5 (0.4±0.8) 2.0 (1.4±2.7) 0.5 (0.4±0.5)
.12 0.5 (0.4±0.9) 0.9 (0.4±1.5)² 0.4 (0.2±0.6)
3 M 57 93 Before 3.8 (3.4±4.7) 6.2 (5.2±7.2) 1.0 (0.9±1.1)
1±3 2.3 (1.4±3.0)** 2.6 (1.7±3.3)** 0.5 (0.4±0.6)**
3±12 2.8 (2.3±3.2) 2.9 (1.9±3.3) 0.5 (0.4±0.6)
.12 1.7 (0.4±3.1)²² 2.7 (1.6±4.5) 0.5 (0.2±0.7)
4 M 62 51 Before 0.6 (0.4±1.3) 2.9 (2.3±4.4) 1.0 (0.8±1.3)
1±3 0.4 0.4 0.3
3±12 0.6 (0.4±1.1) 0.9 (0.4±1.3)** 0.4 (0.3±0.4)**
.12 0.5 (0.4±1.0) 0.7 (0.4±1.6) 0.4 (0.2±0.6)
5 M 62 44 Before 0.5 (0.4±0.8) 2.2 (1.4±3.6) 0.8 (0.6±1.0)
1±3 1.6 Ð 0.9
3±12 0.5 (0.4±0.7) 2.8 (0.4±6.0) 0.6 (0.5±0.9)
.12 0.4 (0.4±0.4) 0.6 (0.4±1.0)² 0.4 (0.2±0.5)
6 M 70 41 Before 1.1 (1.0±1.2) 2.3 (1.8±3.0) 0.8 (0.6±0.9)
1±3 Ð Ð 0.9
3±12 0.7 (0.6±0.7)** 1.7 (1.5±1.9) 0.8 (0.7±0.9)
.12 0.5 (0.4±0.8) 1.0 (0.6±1.7) 0.4 (0.2±0.5)²²
7 M 81 85 Before 1.1 (0.9±1.2) 3.3 (3.3±3.3) 1.3 (1.2±1.4)
1±3 1.5 (1.5±1.5) 1.3 (1.1±1.4)* 0.7 (0.6±0.8)**
3±12 1.7 (0.6±3.0) 0.9 (0.4±1.9) 0.5 (0.5±0.6)
.12 0.8 (0.4±1.5) 1.1 (0.4±2.6) 0.6 (0.4±0.8)
8 M 78 68 Before 3.3 (2.5±3.9) 5.2 (4.2±6.0) 0.3 (0.2±0.4)
1±3 0.9 (0.4±1.3)** 0.5 (0.4±0.7)** 0.2 (0.2±0.2)
3±12 0.8 (0.4±1.6) 1.8 (0.8±3.0) 0.2 (0.2±0.2)
.12 0.8 (0.4±2.2) 1.9 (0.6±2.9) 0.2 (0.2±0.6)
9 F 72 57 Before 0.6 (0.4±1.2) 5.1 (4.3±5.8) 0.4 (0.3±0.6)
1±3 Ð Ð 0.7
3±12 1.2 (0.6±1.8) 2.7 (1.0±4.3)** 0.6 (0.5±0.7)
.12 0.6 (0.4±1.1) 2.6 (1.7±3.5) 0.5 (0.4±0.8)
10 M 67 36 Before 0.4 (0.4±0.4) 1.1 (0.4±1.6) 0.6 (0.4±0.7)
1±3 0.4 0.4 0.5
3±12 Ð Ð Ð
.12 0.4 1.1 Ð
*P , 0.05 and **P , 0.01 vs before treatment; ²P , 0.05 and ²²P , 0.01 vs month 3±12. No statistical evaluation was performed on individual hormone
levels. Normal values in men: LH 1.9±9.2 U/I, FSH 1.6±11.1 U/I, a-subunit 0.4±1.1 mg/l; in postmenopausal women: LH 17.5±86.8 U/I, FSH 26.2±107.7 U/I,
a-subunit 1.3±4.0 mg/l. Pretreatment levels are means of 13 values on a control day. The levels after 1±3, 3±12 and .12 months of therapy are means of
2±5, 2±6 and 4±17 serum samples respectively, except in the few cases when only one value was available.
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patients (all ,25 mg/l). Serum levels of GH, IGF-I, TSH
and ACTH were not elevated in any of the patients. All
patients showed hypopituitarism, with deficient adre-
nal, thyroidal and gonadal function, except patients 3
and 9, who only had deficient gonadal and thyroidal
function respectively. All patients had pituitary macro-
adenomas with suprasellar extension.
The median duration of follow-up under quinagolide
treatment was 57 months (range 36±93 months). PRL
levels remained lower than 2 mg/l during the entire
treatment in all the patients, indicating good compliance.
Tolerance of the drug was excellent in this relatively old
group of patients. No clinically significant nausea,
postural hypotension or psychiatric disturbances were
seen. A significant decrease of serum LH, FSH or a-
subunit concentrations was found in nine patients
(Table 1). No early decrease was seen in the six patients
whose gonadotropin and a-subunit levels were mea-
sured 5 days after the beginning of quinagolide
treatment (data not shown). Response was shown
within the first 12 months of treatment, except in
patient 5 whose FSH levels decreased only after more
than 12 months. In three patients (2, 3 and 6), who
responded within the first year, gonadotropin or a-
subunit levels further decreased after a treatment
duration of more than 12 months. The suppression
was most marked in those patients with the highest
pretreatment levels. The levels remained low during the
entire treatment period. No apparent escape from
treatment was seen, not even in patients 2, 3 and 7,
who were followed for more than 7 years.
The two methods of tumor volume calculation
showed comparable results (correlation coefficient r 
0:95 (Fig. 1). Therefore only the surface summation
method was used for evaluating the effect of quinago-
lide on tumor volume. A volume change of more than
10% was arbitrarily considered significant (Table 2).
During the first year tumor volume decreased in three
patients (patients 3, 5 and 6), remained stable in three
(patients 1, 4, and 7) and increased in four (patients 2,
8, 9 and 10) (Table 2, Fig. 2). In patients 3 and 6,
whose tumor initially decreased in volume, regrowth to
the pretreatment volume occurred after 10 and 24
months respectively. Of the three patients whose tumor
volume initially remained stable, a significant decrease
in volume was shown in patient 1 after 56 months of
treatment, but significant growth occurred in patientsFigure 2. Evolution of tumor volumes (absolute values in cm3).
Table 2 Tumor volume (cm3) before and during treatment with quinagolide.
Quinagolide treatment (months)
Patient 0 (mean) 1±12 (mean (range) and D) 12±48 (mean (range) and D) .48 (mean (range) and D)
1 5.5 5.6 5.8 (5.6±6.1) 4.2
D 1.8 D 5.5 D 223.6*
2 4.7 6.9 (5.4±8.4) 7.1 (6.4±7.8) 7.5 (7.3±7.7)
D 46.8* D 51.1* D 59.6*
3 10.5 8.2 11.5 (10.5±12.4) 12.3 (11.5±13.3)
D 221.9* D 9.5 D 17.1*
4 7.0 7.6 (7.0±8.2) 12.1 (9.7±14.5) 12.6
D 8.6 D 72.9* D 80.0*
5 4.5 2.3 2.2 (2.1±2.4) Ð
D 248.9* D 251.1*
6 3.3 2.9 (2.6±3.1) 3.5 3.4
D 212.1* D 6.1 D 3.0
7 7.1 6.5 7.7 (5.8±9.5) 8.8
D 28.5 D 8.5 D 23.9*
8 11.1 14.6 13.9 (13.2±14.5) 15.4 (13.5±17.3)
D 31.5* D 25.2* D 38.7*
9 5.6 6.5 (6.3±6.6) 6.0 (5.4±6.6) 8.4
D 16.1* D 7.1 D 50.0*
10 5.5 6.1 6.0 Ð
D 10.9* D 9.1 Ð
D  Tumor volume (in cm3) change from baseline (in %).
*A change of more than 10% is arbitrarily considered significant.
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4 and 7 after 24 and 37 months respectively. At the end
of follow-up (range 36±93 months) tumor volume
remained significantly below pretreatment volumes in
two patients (patients 1 and 5), remained at pretreat-
ment volumes in two (patients 6 and 10) and was
significantly increased in six (patients 2, 3, 4, 7, 8 and
9). No relationship between changes in tumor volume
and changes in gonadotropin and/or a-subunit levels
could be demonstrated.
Patients 1, 2, 3, 4, 5, 9 and 10 had no visual field
defects before or during the treatment. In patient 6 a
pre-existing discrete left superior temporal quadrant-
anopsia slightly deteriorated during treatment with
development of bitemporal superior quadrantanopsia,
although no significant increase in tumor volume
could be detected on MRI. In patients 7 and 8, who had
bitemporal superior quadrantanopsia and bitemporal
hemianopsia respectively, visual field defects improved
in the first 4 months of treatment. When tested after 59
and 35 months of treatment respectively, a slight
deterioration was shown in both patients, correlating
with a significant increase in tumor volume. Patient 2,
whose tumor volume was progressively increasing on
successive CT and MRI scans, developed unilateral
ophthalmoplegia (6th cranial nerve) after 83 months of
quinagolide treatment, which responded favorably to
treatment with dexamethasone.
Patients 6 and 10 were eventually operated on.
Pathological examination of the resection specimens
revealed chromophobic adenoma. Immunohistochem-
ical staining was positive for FSH and a-subunit and
negative for PRL and ACTH.
Discussion
Due to advances in immunological and molecular
biological techniques to detect hormonal secretion in
vitro, it has been demonstrated in recent years that the
majority of CNPA are in fact poorly secreting, rather
than completely non-secreting (6±8). In cell culture
they usually synthesize and secrete the gonadotropic
hormones FSH and/or LH, and/or their free a- or b-
subunits (6±8). Even adenomas that have lost all
neuropeptide synthetizing activity (so-called null-cell
adenomas) demonstrate typical dense core neurosecre-
tory granules on electron microscopy, while the
secretory granule-specific protein chromogranin A
can be identified in virtually all cases (30, 31).
The presence of hormonal secretion provides an
opportunity for medical treatment. Dopamine agonists
are an evident option, since CNPA express dopamine
receptors on their cell membranes (11±16), and
addition of dopamine agonists to cultures of tumor
cells of gonadotroph origin suppresses the release and
synthesis of gonadotropins and a-subunits (17±19).
In this study we report on the efficacy of treatment
with the potent non-ergot dopamine agonist quinago-
lide in ten patients with CNPA. The diagnosis was made
on a clinical basis in the presence of a solid pituitary
tumor without clinical signs of hormonal hypersecre-
tion and lacking clinical and radiological character-
istics of non-pituitary tumors. No biopsy material was
available to confirm the diagnosis, because reasons for
choosing quinagolide treatment were either the pre-
sence of relative contraindications to surgery or refusal
of surgery by the patient. The slow growth of the
tumors is compatible with the diagnosis of CNPA (32±
35). Two patients were eventually operated on, and the
diagnosis was confirmed by pathological and immuno-
histochemical examination.
Quinagolide induced a significant decrease of serum
concentrations of LH, FSH or a-subunit in nearly all
patients. Since all our patients showed severe hypopi-
tuitarism this response is probably not due to an effect
on normal gonadotrophs but on gonadotroph produc-
tion by the tumor cells. Levels only decreased after
prolonged treatment, confirming our in vitro data
showing that it takes an incubation of 2±6 weeks
before maximal inhibition of hormonal secretion is
attained (19). The serum concentrations of LH, FSH
and a-subunit remained low during the entire follow-
up period. No escape from treatment was seen, not even
in patients followed for more than 7 years.
In patients with PRL- or GH-producing pituitary
adenomas, drugs that suppress hormonal activity
induce tumor shrinkage in a substantial proportion of
tumors (9, 10). One might expect similar effects in
patients with CNPA. The reported in vivo effects of
bromocriptine treatment on tumor size have been
variable, however (11, 20±24). In general no reduction
in tumor size has been observed, but occasional
patients respond to dopaminergic therapy with
improvement in visual field defects and/or reduction
of tumor mass. In many reports the administered doses
were low and the treatment period short. Based on the
in vitro data, showing suppression of hormone produc-
tion only when high concentrations of dopaminergic
drugs are used for a long time, we hypothesized that
long-term treatment with high doses would be needed
to obtain tumor shrinkage. For this reason we chose
the potent dopamine agonist quinagolide, in a high
daily dose of 0.3 mg, comparable to 30 mg bromo-
criptine. In a preliminary study in five patients, treated
for 12±18 months, promising results were obtained with
tumor shrinkage in one, and improvement in visual field
defects in two (26). Our long-term results in ten patients
do not confirm these observations. During the first year
tumor volume decreased in three patients, but in two of
them regrowth occurred after a few months. In six
patients progressive increase in tumor size occurred
despite sustained suppression of gonadotropin or a-
subunit levels. In two out of three patients with pre-
existing visual field defects a slight improvement was
shown during the first months of treatment, but
eventually deterioration occurred in all three patients.
One patient developed unilateral ophthalmoplegia
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during treatment. At the end of follow-up (median 56
months, range 36±92 months) tumor volume
remained significantly below pretreatment volume in
two patients, remained at pretreatment volume in two
and was significantly increased in six. Thus a convin-
cing tumor-shrinking effect could not be demonstrated.
In the absence of a control group it is difficult to
determine whether quinagolide was effective in slowing
down tumor growth or not. Only a long-term large-
scale multicenter prospective randomized placebo-
controlled trial could give an answer to this question.
A large number of patients would be needed to
demonstrate small effects on tumor volume. A treat-
ment of several years would be needed because these
tumors are usually slow growing (32±35). Our results
clearly indicate that such a controlled study is not
feasible in non-selected patients with CNPA.
Drugs that suppress hormone production only
induce significant shrinkage of active endocrine cells
containing a well-developed secretory apparatus (9,
10). Organelles involved in the synthesis and storage of
hormones, such as the endoplasmic reticulum and the
secretory vesicles, make a substantially smaller con-
tribution to the tumor volume in CNPA than, for
example, in prolactinomas. It is therefore not surprising
that an improvement of visual field defects or a tumor
size reduction during dopamine agonist treatment has
been reported in a greater percentage of patients with
pituitary adenomas that hypersecrete gonadotropins or
a-subunits than in patients without apparent over-
production (11,20±24). Such hypersecreting CNPA are
rare, however, making a randomized controlled study
in these selected patients practically impossible.
Another possible explanation for the discrepancy
between the efficient suppression of hormone produc-
tion by quinagolide and the disappointing effects on
tumor volume could be the inclusion of tumors with a
very low dopamine receptor density. This problem can
now be approached by dopamine receptor scintigraphy
with 123I-IBZM or preferably with 123I-epidepride (13±
16). These nuclear medicine techniques can predict the
suppressive effect of dopamine agonists on the growth
of prolactinomas. In a recent study we demonstrated
tumor shrinkage in two and tumor stabilization in one
of three 123I-IBZM single photon emission computed
tomography (SPECT)-positive CNPA patients treated
with quinagolide, although in one of these patients an
additional effect of octreotide could not be excluded
(14). In one of four patients without 123I-IBZM uptake
in the pituitary fossa tumor growth occurred under
quinagolide therapy. Feasibility studies on a larger
number of patients with longer follow-up are needed to
validate whether SPECT with 123I-IBZM or 123I-
epidepride might be of assistance in selecting patients
who may potentially benefit from dopaminergic ther-
apy.
In conclusion, long-term treatment of patients with
CNPA with high doses of the dopamine agonist
quinagolide could not prevent progressive increase in
tumor size in most patients, despite persistent suppres-
sion of hormone secretion. It remains unproven
whether quinagolide retards CNPA growth. Additional
studies are needed to investigate whether subgroups of
patients, e.g. those with positive dopamine receptor
scintigraphy or those with marked hypersecretion of
intact gonadotropins or subunits, will respond more
favorably to treatment with dopamine agonists. Feasi-
bility studies in selected subgroups should be performed
before large prospective randomized placebo-controlled
trials are organized.
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